Table 1.
Mean PsA-modified vdH-S scores at baseline for DISCOVER-2 patients included in reading sessions 1, 2 and 3
|
|
Guselkumab Q4W | Guselkumab Q8W | Placebo→guselkumab Q4W |
| Baseline vdH-S score | |||
| Reading session 1* | |||
| Patients, N | 245 | 248 | 246 |
| Total | 27.2 (42.3) | 23.0 (37.7) | 23.8 (37.8) |
| Erosion | 13.3 (22.4) | 11.6 (20.3) | 11.0 (19.1) |
| Joint space narrowing | 13.9 (21.5) | 11.5 (18.3) | 12.7 (19.9) |
| Reading session 2† | |||
| Patients, N | 232 | 238 | 231 |
| Total | 25.4 (40.2) | 22.4 (37.9) | 23.0 (39.5) |
| Erosion | 15.1 (22.2) | 13.6 (20.8) | 13.3 (21.4) |
| Joint space narrowing | 10.3 (19.5) | 8.8 (17.9) | 9.7 (19.1) |
| Reading session 3‡ | |||
| Patients, N | 221 | 228 | 215 |
| Total | 28.0 (43.6) | 23.9 (40.4) | 25.6 (42.4) |
| Erosion | 14.2 (23.3) | 12.0 (21.9) | 12.1 (21.9) |
| Joint space narrowing | 13.8 (21.8) | 11.9 (19.5) | 13.5 (21.6) |
Data reported as mean (SD).
*Reading session 1 included randomised patients who received ≥1 administration of study drug (partial or complete) and had radiographic images obtained at weeks 0 and 24 (or at discontinuation prior to week 24).
†Reading session 2 included patients continuing study treatment at week 24 with images at weeks 0, 24 and 52 (or at discontinuation after week 24).
‡Reading session 3 included patients continuing study treatment at week 52 with images at weeks 0, 24, 52 and 100 (or at discontinuation after week 52).
PsA-modified vdH-S score, van der Heijde-Sharp score modified for psoriatic arthritis; Q4W, every 4 weeks; Q8W, every 8 weeks.